MOUNTAIN VIEW, Calif.,
March 24, 2021 /PRNewswire/
-- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq:
ADTX), a biotech innovation company focused on improving the health
of the immune system, today announced that its
AditxtReprogrammingTM Therapeutics Division is preparing
its therapeutic program for psoriasis for First-In-Human clinical
trials. The trials, which are planned to begin in Q4 2021, will
evaluate clinical safety and efficacy of Aditxt's new approach to
reprogramming and retraining the immune system.
The Trials will be evaluating a nucleic acid-based technology
named Apoptotic DNA Immunotherapy™ (ADi™). Aditxt's
ADi™ technology utilizes a novel approach that mimics the way
the body naturally induces tolerance to its own tissues
(therapeutically induced immune tolerance) and is protected with
approximately 90 U.S. and international patents. ADi™ has
demonstrated efficacy in several pre-clinical disease models
including psoriasis in which a reduction in skin thickening and
scaling, and modulation of key protein markers were observed.
Aditxt has signed an agreement with a regulatory consultant
based in Munich, Germany, which
will play a central role in navigating the first
AditxtReprogrammingTM therapeutic program through the
clinical trial and regulatory process. The firm will work
with the Aditxt's AditxtReprogrammingTM team to submit
an Investigational New Drug application (IND) to the regulatory
agency in Germany. Psoriasis
is the first indication being targeted for clinical trial in the
AditxtReprogrammingTM therapeutics pipeline. Other
candidates that are advancing toward clinical trials include ADi™
for type 1 diabetes and skin allografting.
Amro Albanna, co-founder and
Chief Executive Officer of Aditxt, stated, "this agreement
represents a major step forward as we begin advancing ADi™ for
psoriasis through the regulatory process and towards the start of
clinical trials. Our co-founder and Chief Innovation Officer, Dr.
Shahrokh Shabahang, and his product
development team have experience working within the regulatory
framework of both the U.S. and Europe and are leading all preparation,
execution, regulatory and budgetary matters relating to Aditxt's
planned 2021 Phase I/IIA clinical trials for psoriasis. We are
excited to begin this phase of Aditxt's development after our
initial focus on launching the AditxtScoreTM
platform for monitoring the immune system."
For more information about AditxtReprogrammingTM,
visit aditxt.com/.
About Aditx Therapeutics
Aditxt is developing
technologies specifically focused on improving the health of the
immune system through immune monitoring and reprogramming. The
Company's immune monitoring technology is designed to provide a
personalized comprehensive profile of the immune system. The
Company's immune reprogramming technology is designed to retrain
the immune system to induce tolerance with an objective of
addressing rejection of transplanted organs, autoimmune diseases,
and allergies. For more information, please visit:
www.aditxt.com
Forward-Looking Statements
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of the federal securities laws. Forward looking statements
include statements regarding the Company's intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the Company's ongoing and planned product
development; the Company's intellectual property position; the
Company's ability to develop commercial functions; expectations
regarding product launch and revenue; the Company's results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section entitled "Risk Factors" in the Company's
prospectus, dated February 10, 2021,
that was filed with the Securities and Exchange Commission under
File No. 333-252711, as well as discussions of potential risks,
uncertainties, and other important factors in the Company's
subsequent filings with the Securities and Exchange Commission. All
such statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aditxt-to-initiate-first-in-human-clinical-trials-with-its-therapeutics-programs-in-psoriasis-by-year-end-301254455.html
SOURCE Aditxt